医学
哮喘
恶化
支气管高反应性
自然史
肺功能
人口
儿科
疾病
自发缓解
重症监护医学
内科学
肺
呼吸道疾病
替代医学
病理
环境卫生
作者
Dennis Thomas,Vanessa M. McDonald,Ian Douglas Pavord,Peter G. Gibson
出处
期刊:The European respiratory journal
[European Respiratory Society]
日期:2022-03-31
卷期号:60 (5): 2102583-2102583
被引量:303
标识
DOI:10.1183/13993003.02583-2021
摘要
Asthma treatment goals currently focus on symptom and exacerbation control rather than remission. Remission is not identical to cure, but is a step closer. This review considers the current definitions of remission in asthma, the prevalence and predictors, the pathophysiology of remission, the possibility of achieving it using the available treatment options, and the future research directions. Asthma remission is characterised by a high level of disease control, including the absence of symptoms and exacerbations, and normalisation or optimisation of lung function with or without ongoing treatment. Even in those who develop a symptomatic remission of asthma, persistent pathological abnormalities are common, leading to a risk of subsequent relapse at any time. Complete remission requires normalisation or stabilisation of any underlying pathology in addition to symptomatic remission. Remission is possible as part of the natural history of asthma, and the prevalence of remission in the adult asthma population varies between 2% and 52%. The factors associated with remission include mild asthma, better lung function, better asthma control, younger age, early-onset asthma, shorter duration of asthma, milder bronchial hyperresponsiveness, fewer comorbidities and smoking cessation or never smoking. Although previous studies have not targeted treatment-induced remission, there is some evidence to show that the current long-term add-on therapies such as biologics and azithromycin can achieve some criteria for asthma remission on treatment, at least in a subgroup of patients. However, more research is required. Long-term remission could be included as a therapeutic goal in studies of asthma treatments.
科研通智能强力驱动
Strongly Powered by AbleSci AI